Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib, Letrozole, and T-DM1 in ER+/HER2+ Metastatic Breast Cancer
NCT03709082Phase 2Terminated
- Sponsor
- University of Kansas Medical Center
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in breast cancer, HER2-positive breast cancer, estrogen receptor-positive breast cancer (ER+), sponsored by University of Kansas Medical Center. Started Oct 2018; status: terminated.
02
Drugs
palbociclib
03
Conditions
breast cancerHER2-positive breast cancerestrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT03709082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709082.